Payment overview · 2025
General Payments
$396.61
19 reported records · 9 companies
Healthcare provider profile · identity verified
Chandra Shekar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENVILLE, AL · NPI 1881889624
Verified facts
What the public records show
CMS Open Payments records show Chandra Shekar, M.D. received $396.61 in general payments during 2025 across 19 reported records.
Verona Pharma, Inc. accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $119.47 | 30.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.85 | 15.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.58 | 14.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 9.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $36.94 | 9.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.79 | 8.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.47 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.93 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.88 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.91 | 17 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $119.47 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.58 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.58 | 3 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $36.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amoxicillin | Amoxicillin | 171 | 84 |
| Topiramate | Topiramate | 159 | 54 |
| Bupropion Xl | Bupropion Hcl | 157 | 61 |
| Pregabalin | Pregabalin | 147 | 44 |
| Mounjaro | Tirzepatide | 134 | 32 |
| Clonidine Hcl | Clonidine Hcl | 112 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 36 |
| Naltrexone Hcl | Naltrexone Hcl | 110 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 40 |
| Omeprazole | Omeprazole | 98 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 94 | 37 |
| Fluconazole | Fluconazole | 93 | 54 |
| Gabapentin | Gabapentin | 88 | 30 |
| Linzess | Linaclotide | 88 | 35 |
| Ibuprofen | Ibuprofen | 85 | 26 |
| Ozempic | Semaglutide | 85 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 17 |
| Metformin Hcl | Metformin Hcl | 78 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 76 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 75 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 29 |
| Azithromycin | Azithromycin | 70 | 48 |
| Allopurinol | Allopurinol | 65 | 24 |
| Farxiga | Dapagliflozin Propanediol | 58 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 18 |
| Tramadol Hcl | Tramadol Hcl | 55 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 17 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Furosemide | Furosemide | 53 | 24 |
| Montelukast Sodium | Montelukast Sodium | 53 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Lovastatin | Lovastatin | 50 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 29 |
| Jardiance | Empagliflozin | 49 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 48 | 16 |
| Meloxicam | Meloxicam | 48 | 23 |
| Naproxen | Naproxen | 45 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 42 | 14 |
| Guanfacine Hcl Er | Guanfacine Hcl | 41 | 23 |
| Methotrexate | Methotrexate Sodium | 41 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 20 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 40 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 11 |
| Levofloxacin | Levofloxacin | 37 | 21 |
| Mirtazapine | Mirtazapine | 37 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 23 |
| Cephalexin | Cephalexin | 36 | 19 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 36 | 15 |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Carvedilol | Carvedilol | 35 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 17 |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Losartan Potassium | Losartan Potassium | 33 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Baclofen | Baclofen | 32 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 13 |
| Simvastatin | Simvastatin | 31 | 11 |
| Trazodone Hcl | Trazodone Hcl | 31 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 29 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 13 |
| Eliquis | Apixaban | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 15 |
| Lisinopril | Lisinopril | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Abilify Maintena | Aripiprazole | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Prednisone | Prednisone | 22 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Lactulose | Lactulose | 21 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Indomethacin | Indomethacin | 20 | 11 |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 13 |
| Famotidine | Famotidine | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | 12 |
| Metformin Hcl Er | Metformin Hcl | 15 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Tezspire | Tezepelumab-Ekko | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.61 · 19 records | Verona Pharma, Inc. | BREZTRI, CAPLYTA, Cologuard Collection Kit, GLASSIA, JARDIANCE, Ohtuvayre, REXULTI, TRELEGY ELLIPTA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error